Purple Biotech Drug Patent Portfolio
Purple Biotech owns 1 orange book drug protected by 5 US patents Given below is the list of Purple Biotech's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10350171 | Celecoxib and amlodipine formulation and method of making the same | 14 Jun, 2038 | Active |
| US10925835 | Celecoxib and amlodipine formulation and method of making the same | 14 Jun, 2038 | Active |
| US10945960 | Celecoxib and amlodipine formulation and method of making the same | 14 Jun, 2038 | Active |
| US9408837 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs | 28 Feb, 2030 | Active |
| US9662315 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs | 22 May, 2029 | Active |
Latest Legal Activities on Purple Biotech's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Purple Biotech.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Jan, 2023 | US10350171 |
|
Recordation of Patent Grant Mailed
Critical
| 16 Mar, 2021 | US10945960 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 Mar, 2021 | US10945960 |
|
Issue Notification Mailed
Critical
| 24 Feb, 2021 | US10945960 |
|
Recordation of Patent Grant Mailed
Critical
| 23 Feb, 2021 | US10925835 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Feb, 2021 | US10925835 |
| Dispatch to FDC | 10 Feb, 2021 | US10945960 |
|
Application Is Considered Ready for Issue
Critical
| 10 Feb, 2021 | US10945960 |
|
Issue Fee Payment Received
Critical
| 08 Feb, 2021 | US10945960 |
|
Issue Fee Payment Verified
Critical
| 08 Feb, 2021 | US10945960 |
|
Mail Notice of Allowance
Critical
| 03 Feb, 2021 | US10945960 |
|
Issue Notification Mailed
Critical
| 03 Feb, 2021 | US10925835 |
|
Notice of Allowance Data Verification Completed
Critical
| 31 Jan, 2021 | US10945960 |
| Dispatch to FDC | 28 Jan, 2021 | US10925835 |
|
Application Is Considered Ready for Issue
Critical
| 20 Jan, 2021 | US10925835 |
Purple Biotech's Family Patents
Purple Biotech drugs have patent protection in a total of 8 countries. It has a significant patent presence in the US with 68.2% of its patents being US patents. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Purple Biotech Drug List
Given below is the complete list of Purple Biotech's drugs and the patents protecting them.
1. Consensi
Consensi is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10350171 | Celecoxib and amlodipine formulation and method of making the same |
14 Jun, 2038
(13 years from now)
| Active |
| US10925835 | Celecoxib and amlodipine formulation and method of making the same |
14 Jun, 2038
(13 years from now)
| Active |
| US10945960 | Celecoxib and amlodipine formulation and method of making the same |
14 Jun, 2038
(13 years from now)
| Active |
| US9408837 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
28 Feb, 2030
(5 years from now)
| Active |
| US9662315 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
22 May, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Consensi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List